R. Bannerji

发表

Randomized phase 2 study of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus erlotinib in patients with non-small cell lung cancer.

J. Nemunaitis, M. Edelman, J. Stephenson, 2014, Lung cancer.

Retroviral vector-mediated gamma-interferon gene transfer into tumor cells generates potent and long lasting antitumor immunity.

E. Gilboa, K. Cronin, B. Gansbacher, 1990, Cancer research.

The role of IL-2 secreted from genetically modified tumor cells in the establishment of antitumor immunity.

E. Gilboa, C. Cordon-Cardo, R. Bannerji, 1994, Journal of immunology.

Variability and genotype × cutting interactions for different nutritional components in Chenopodium album L.

A. Bhargava, S. Shukla, R. Bannerji, 2018 .

Phase I study of the CDK inhibitor dinaciclib (SCH 727965) in patients (pts) with relapsed/refractory CLL.

J. Byrd, N. Heerema, K. Blum, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Influenza Adherence Tool Kit: Implementation and evaluation among allogeneic hematopoietic transplantation recipients

R. Bannerji, T. Krimmel, Maribel Borysyuk, 2017, Clinical journal of oncology nursing.

Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial.

A. Rosenwald, R. Advani, A. Chaudhry, 2022, The Lancet. Haematology.

Pembrolizumab plus dinaciclib in patients with hematologic malignancies: the phase 1b KEYNOTE-155 study

Shaji K. Kumar, F. Hernandez-Ilizaliturri, J. Pagel, 2021, Blood advances.

Dinaciclib is a Novel Cyclin Dependent Kinase Inhibitor with Significant Clinical Activity in Relapsed and Refractory Chronic Lymphocytic Leukemia

Jeffrey A Jones, M. Grever, J. Byrd, 2015, Leukemia.

Impact of Insurance Status on Survival Outcomes in Adults With Acute Lymphoblastic Leukemia (ALL): A Single-center Experience.

W. Shih, R. Bannerji, Gratian Salaru, 2020, Clinical lymphoma, myeloma & leukemia.

Apoptotic-Regula tory a nd C omplement-Prote cting P rotein Expression i n C hronic L ymphocytic L eukemia: R elationship t o In V ivo R ituximab R esistance

J. Byrd, I. Flinn, J. Reed, 2003 .

A first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies

J. Nemunaitis, P. Kirschmeier, Ying‐Ming Jou, 2013, Journal of Translational Medicine.

Augmentation of antitumor immunity by tumor cells transduced with a retroviral vector carrying the interleukin-2 and interferon-gamma cDNAs.

B. Gansbacher, D. Golde, F. Rosenthal, 1994, Blood.

Regression of bladder tumors in mice treated with interleukin 2 gene- modified tumor cells [published erratum appears in J Exp Med 1993 Jun 1;177(6):following 1831]

E. Gilboa, W. Fair, W. Heston, 1993, The Journal of experimental medicine.

Anti‐metastatic vaccination of tumor‐bearing mice with il‐2‐gene‐inserted tumor cells

E. Gilboa, A. Porgador, B. Gansbacher, 1993, International journal of cancer.

CLINICAL ACTIVITY OF REGN1979, AN ANTI‐CD20 X ANTI‐CD3 BISPECIFIC ANTIBODY (AB) IN PATIENTS (PTS) WITH (W/) RELAPSED/REFRACTORY (R/R) B‐CELL NON‐HODGKIN LYMPHOMA (B‐NHL)

A. Rosenwald, S. Ansell, G. Yancopoulos, 2019, Hematological Oncology.

Immunotherapy of prostate cancer in the Dunning rat model: use of cytokine gene modified tumor vaccines.

E. Gilboa, W. Fair, J. Vieweg, 1994, Cancer research.

Immunotherapies Old and New: Hematopoietic Stem Cell Transplant, Chimeric Antigen Receptor T Cells, and Bispecific Antibodies for the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma

R. Bannerji, M. Shah, Anupama Doraiswamy, 2021, Current Hematologic Malignancy Reports.

Baseline Biomarkers of T-Cell Function Correlate with Clinical Responses to Odronextamab (REGN1979), and Loss of CD20 Target Antigen Expression Identified As a Mechanism of Treatment Resistance

R. Advani, A. Dhanik, A. Chaudhry, 2020 .

Clinical Activity of REGN1979, a Bispecific Human, Anti-CD20 x Anti-CD3 Antibody, in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL)

R. Advani, A. Murphy, S. Ansell, 2019, Blood.

Antimetastatic vaccination of tumor-bearing mice with two types of IFN-gamma gene-inserted tumor cells.

E. Gilboa, A. Porgador, Y. Watanabe, 1993, Journal of immunology.

Choline-magnesium trisalicylate modulates acute myelogenous leukemia gene expression during induction chemotherapy

A. Rabson, R. Strair, J. Aisner, 2017, Leukemia & lymphoma.

Clinical and laboratory studies of the novel cyclin-dependent kinase inhibitor dinaciclib (SCH 727965) in acute leukemias

E. Sausville, I. Gojo, E. Feldman, 2013, Cancer Chemotherapy and Pharmacology.

Immunotherapy of bladder cancer with cytokine gene-modified tumor vaccines.

E. Gilboa, W. Fair, B. Gansbacher, 1994, Cancer research.

Prognostic Factors for Complete Response to Ibrutinib in Patients With Chronic Lymphocytic Leukemia: A Pooled Analysis of 2 Clinical Trials

J. Byrd, T. Kipps, S. O'brien, 2018, JAMA oncology.

The novel cyclin-dependent kinase inhibitor dinaciclib (SCH727965) promotes apoptosis and abrogates microenvironmental cytokine protection in chronic lymphocytic leukemia cells

Jeffrey A Jones, Lisa L. Smith, M. Grever, 2012, Leukemia.

Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity

E. Gilboa, K. Cronin, B. Gansbacher, 1990, The Journal of experimental medicine.

Phase 1 safety, pharmacokinetic and pharmacodynamic study of the cyclin-dependent kinase inhibitor dinaciclib administered every three weeks in patients with advanced malignancies

Jennifer L Moseley, L. Chirieac, G. Shapiro, 2017, British Journal of Cancer.

Effect of aprepitant on the pharmacokinetics of the cyclin-dependent kinase inhibitor dinaciclib in patients with advanced malignancies

G. Shapiro, M. Mita, Da Zhang, 2012, Cancer Chemotherapy and Pharmacology.

Cyclin-dependent kinase inhibitor Dinaciclib (SCH727965) inhibits pancreatic cancer growth and progression in murine xenograft models

G. Feldmann, A. Maitra, M. Hidalgo, 2011, Cancer biology & therapy.

Randomized phase II trial of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus capecitabine in patients with advanced breast cancer.

C. Shapiro, M. Mita, A. Mita, 2014, Clinical breast cancer.

A phase I study of the CDK inhibitor dinaciclib (SCH 727965) administered every 3 weeks in patients (pts) with advanced malignancies: Final results.

L. Chirieac, G. Shapiro, S. Rodig, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of SCH 727965, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies.

J. Nemunaitis, P. Kirschmeier, D. Khaira, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Combined Inhibition of Cyclin-Dependent Kinases (Dinaciclib) and AKT (MK-2206) Blocks Pancreatic Tumor Growth and Metastases in Patient-Derived Xenograft Models

Chaoxin Hu, Barry D. Nelkin, A. Maitra, 2015, Molecular Cancer Therapeutics.

Genetics and Biology of Retroviral Vectors

R. Bannerji, 1995 .

Alemtuzumab-induced syndrome of inappropriate anti-diuretic hormone

R. Bannerji, Jeffrey S. Kunz, 2005, Leukemia & lymphoma.

Apoptotic-regulatory and complement-protecting protein expression in chronic lymphocytic leukemia: relationship to in vivo rituximab resistance.

J. Byrd, I. Flinn, John Calvin Reed, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Update on the biology of chronic lymphocytic leukemia.

J. Byrd, R. Bannerji, John C. Byrd, 2000, Current opinion in oncology.

Erratum: Regression of bladder tumors in mice treated with interleukin 2 gene-modified tumor cells (Journal of Experimental Medicine (April 1993) 177 (1127))

E. Gilboa, W. Fair, W. Heston, 1993 .

Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort.

S. Opat, C. Tam, A. Tedeschi, 2022, Blood.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Charles J. Vaske, Rohan N. Borkar, Brian D. Kelly, 2016, Journal of Immunotherapy for Cancer.

Update on the Phase I Study of the Cyclin Dependent Kinase Inhibitor Dinaciclib (SCH 727965) In Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL): Confirmation of Clinical Activity and Feasibility of Long-Term Administration

Jeffrey A Jones, M. Grever, J. Byrd, 2010 .

Targeting MCL‐1 and BCL‐2 with polatuzumab vedotin and venetoclax overcomes treatment resistance in R/R non‐Hodgkin lymphoma: Results from preclinical models and a Phase Ib study

Dhara N. Amin, N. Johnson, M. Krem, 2023, American journal of hematology.

Fixed-duration (FD) first-line treatment (tx) with ibrutinib (I) plus venetoclax (V) for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): Primary analysis of the FD cohort of the phase 2 captivate study.

T. Kipps, S. Opat, C. Tam, 2021 .

A phase I dose-escalation study of the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of the novel cyclin-dependent kinase inhibitor SCH 727965 administered every 3 weeks in subjects with advanced malignancies

Jennifer L Moseley, G. Shapiro, C. Takimoto, 2008 .

Odronextamab (REGN1979), a Human CD20 x CD3 Bispecific Antibody, Induces Durable, Complete Responses in Patients with Highly Refractory B-Cell Non-Hodgkin Lymphoma, Including Patients Refractory to CAR T Therapy

R. Advani, A. Chaudhry, S. Ansell, 2020 .

Polatuzumab Vedotin Plus Venetoclax with Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Primary Efficacy Analysis of a Phase Ib/II Study

C. Flowers, P. Marlton, T. Phillips, 2020 .

Phase 1 Study of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody, in Patients with CD20+ B-Cell Malignancies Previously Treated with CD20-Directed Antibody Therapy

R. Advani, S. Ansell, I. Lowy, 2016 .

Safety and Preliminary Clinical Activity of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with B-NHL Previously Treated with CD20-Directed Antibody Therapy

R. Advani, S. Ansell, I. Lowy, 2017 .

The Cyclin Dependent Kinase Inhibitor SCH 727965 Demonstrates Promising Pre-Clinical and Early Clinical Activity in Chronic Lymphocytic Leukemia.

Jeffrey A Jones, Lisa L. Smith, M. Grever, 2009 .

Treatment Discontinuation Patterns for Patients With Chronic Lymphocytic Leukemia in Real-World Settings: Results From a Multi-Center International Study.

M. Davids, A. Schuh, Jennifer R. Brown, 2023, Clinical lymphoma, myeloma & leukemia.

Abstract 2242: A randomized phase 2 study of the cyclin-dependent kinase (CDK) inhibitor Dinaciclib (SCH 727965) in patients with non-small cell lung cancer (NSCLC)

J. Nemunaitis, M. Edelman, J. Stephenson, 2011 .

Regression of bladder tumors in mice treated with interleukin 2 gene- modified tumor cells [published erratum appears in J Exp Med 1993 Jun 1;177(6):following 1831]

E. Gilboa, W. Fair, W. Heston, 1993, The Journal of experimental medicine.

Dinaciclib (SCH 727965) Is a Novel Cyclin-Dependent Kinase (CDK) Inhibitor That Exhibits Activity In Patients With Relapsed Or Refractory Chronic Lymphocytic Leukemia (CLL)

Jeffrey A Jones, M. Grever, J. Byrd, 2013 .

Mosunetuzumab with Lenalidomide Augmentation As First-Line Therapy for Follicular (FL) and Marginal Zone Lymphoma (MZL)

P. Dubielecka, R. Bannerji, A. Olszewski, 2022, Blood.

Abstract CT133: Targeting BCL-2 and MCL-1 overcomes treatment resistance in relapsed and refractory non-Hodgkin lymphoma: Pre-clinical rationale and results from an open-label phase 1b study

Dhara N. Amin, C. Flowers, M. Krem, 2020 .

Polatuzumab vedotin + obinutuzumab + venetoclax in patients with relapsed/refractory (R/R) follicular lymphoma (FL): Primary analysis of a phase 1b/2 trial.

C. Flowers, P. Marlton, T. Phillips, 2021 .

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Charles J. Vaske, Rohan N. Borkar, David M. Schauder, 2016, Journal for ImmunoTherapy of Cancer.

Cyclin-dependent kinase inhibitor Dinaciclib (SCH727965) inhibits pancreatic cancer growth and progression in murine xenograft models

G. Feldmann, A. Maitra, M. Hidalgo, 2011, Cancer biology & therapy.

Emerging Clinical Activity of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Follicular Lymphoma (FL), Diffuse Large B-Cell Lymphoma (DLBCL), and Other B-Cell Non-Hodgkin Lymphoma (B-NHL) Subtypes

R. Advani, S. Ansell, I. Lowy, 2018, Blood.